Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.
Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.
Metformin combination products
Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
Metformin for the Treatment of Unexplained Oligozspermia
- Conditions
- Infertility
- Interventions
- First Posted Date
- 2012-02-08
- Last Posted Date
- 2015-08-07
- Lead Sponsor
- The Egyptian IVF-ET Center
- Target Recruit Count
- 600
- Registration Number
- NCT01529177
- Locations
- 🇪🇬
The Egyptian IVF-ET center, Cairo, Egypt
VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2012-02-07
- Last Posted Date
- 2020-09-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2004
- Registration Number
- NCT01528254
- Locations
- 🇹🇷
Novartis Investigative Site, Kahramanmaras, Turkey
Metformin in Children With Relapsed or Refractory Solid Tumors
- Conditions
- Primary Brain TumorsSolid Tumors
- Interventions
- First Posted Date
- 2012-02-07
- Last Posted Date
- 2023-01-13
- Target Recruit Count
- 26
- Registration Number
- NCT01528046
- Locations
- 🇺🇸
Primary Children's Medical Center/Utah, Salt Lake City, Utah, United States
🇺🇸Nemours Children's Clinic, Jacksonville, Florida, United States
🇺🇸University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Spironolactone Plus Metformin in Polycystic Ovary Syndrome
- Conditions
- Polycystic Ovary Syndrome
- Interventions
- First Posted Date
- 2012-02-06
- Last Posted Date
- 2012-02-06
- Lead Sponsor
- University Magna Graecia
- Target Recruit Count
- 56
- Registration Number
- NCT01526616
Assessment of Blood Glucose Changes in Healthy Volunteers After BMS-754807 Alone or BMS-754807 With Metformin
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2012-02-03
- Last Posted Date
- 2012-06-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 26
- Registration Number
- NCT01525823
- Locations
- 🇦🇺
Local Institution, Melbourne, Victoria, Australia
FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2012-02-02
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 102
- Registration Number
- NCT01524705
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸Joslin Diabetes Center, Boston, Massachusetts, United States
🇺🇸University of Washington, Seattle, Washington, United States
Metformin Effects on Oxidative Stress Parameters in Newly Diagnosed Type 2 Diabetes Patients
- First Posted Date
- 2012-01-30
- Last Posted Date
- 2012-01-31
- Lead Sponsor
- Tehran University of Medical Sciences
- Target Recruit Count
- 108
- Registration Number
- NCT01521624
- Locations
- 🇮🇷
Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of
Treatment Intensification With Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Inadequately Controlled on Sitagliptin and Metformin
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2012-01-27
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 582
- Registration Number
- NCT01519674
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey
Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2016-10-14
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 451
- Registration Number
- NCT01517412
- Locations
- 🇨🇿
Investigational Site Number 203104, Plzen, Czech Republic
🇵🇱Investigational Site Number 616106, Bytom, Poland
🇵🇱Investigational Site Number 616105, Wroclaw, Poland
Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both Medications
- Conditions
- Type 2 Diabetes
- Interventions
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 62
- Registration Number
- NCT01518101
- Locations
- 🇩🇪
Novartis Investigative Site, Völlkingen, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.